Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' MCLAIN D' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 42 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Olencki, T; Peereboom, D; Wood, L; Budd, GT; Novick, A; Finke, J; McLain, D; Elson, P; Bukowski, RM
      Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    2. Hussein, MA; Sandstrom, K; Elson, P; Finke, J; McLain, D; Rayman, P; Rybicki, LA; Bukowski, RA
      GM-CSF safety and effects in the management of advanced/refractory multiple myeloma patients: a phase I trial

      JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
    3. Olencki, T; Finke, J; Tubbs, R; Elson, P; McLain, D; Herzog, P; Budd, GT; Gunn, H; Bukowski, RM
      Phase 1 trial of subcutaneous IL-6 in patients with refractory cancer: Clinical and biologic effects

      JOURNAL OF IMMUNOTHERAPY
    4. van Stolk, R; Stoner, G; Hayton, WL; Chan, K; DeYoung, B; Kresty, L; Kemmenoe, BH; Elson, P; Rybicki, L; Church, J; Provencher, K; McLain, D; Hawk, E; Fryer, B; Kelloff, G; Ganapathi, R; Budd, GT
      Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis

      CLINICAL CANCER RESEARCH
    5. Pelley, R; Ganapathi, R; Wood, L; Rybicki, L; McLain, D; Budd, GT; Peereboom, D; Olencki, T; Bukowski, RM
      A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    6. Chidiac, T; Budd, GT; Pelley, R; Sandstrom, K; McLain, D; Elson, P; Crownover, R; Marks, K; Muschler, G; Joyce, M; Zehr, R; Bukowski, R
      Phase II trial of liposomal doxorubicin (Doxil (R)) in advanced soft tissue sarcomas

      INVESTIGATIONAL NEW DRUGS
    7. Wolkomir, R; McLain, D
      Shod for snow - Whether they're strapping on traditional or high-tech footgear, snowshoers are mushing into winter

      SMITHSONIAN
    8. Holland, MM; Burk, CJ; McLain, D
      Long-term vegetation dynamics of the lower strata of a western Massachusetts oxbow swamp forest

      RHODORA
    9. Bukowski, RM; Rayman, P; Molto, L; Tannenbaum, CS; Olencki, T; Peereboom, D; Tubbs, R; McLain, D; Budd, GT; Griffin, T; Novick, A; Hamilton, TA; Finke, J
      Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma

      CLINICAL CANCER RESEARCH
    10. Budd, GT; Ganapathi, R; Wood, L; Snyder, J; McLain, D; Bukowski, RM
      Approaches to managing carboplatin-induced thrombocytopenia: Focus on the role of amifostine

      SEMINARS IN ONCOLOGY
    11. BUDD GT; ADAMSON PC; GUPTA M; HOMAYOUN P; SANDSTROM SK; MURPHY RF; MCLAIN D; TUASON L; PEEREBOOM D; BUKOWSKI RM; GANAPATHI R
      PHASE I II TRIAL OF ALL-TRANS-RETINOIC ACID AND TAMOXIFEN IN PATIENTSWITH ADVANCED BREAST-CANCER/

      Clinical cancer research
    12. BUDD GT; ADAMSON PC; GUPTA M; HOMAYOUN P; SANDSTROM SK; MURPHY RF; MCLAIN D; TUASON L; PEEREBOOM D; BUKOWSKI RM; GANAPATHI R
      PHASE I II TRIAL OF ALL-TRANS-RETINOIC ACID AND TAMOXIFEN IN PATIENTSWITH ADVANCED BREAST-CANCER/

      Clinical cancer research
    13. BUKOWSKI RM; RAYMAN P; UZZO R; BLOOM T; SANDSTROM K; PEEREBOOM D; OLENCKI T; BUDD GT; MCLAIN D; ELSON P; NOVICK A; FINKE JH
      SIGNAL-TRANSDUCTION ABNORMALITIES IN T-LYMPHOCYTES FROM PATIENTS WITHADVANCED RENAL-CARCINOMA - CLINICAL RELEVANCE AND EFFECTS OF CYTOKINETHERAPY

      Clinical cancer research
    14. MCLAIN D
      CLINICAL-FEATURES OF ANA-POSITIVE AND ANA-NEGATIVE PATIENTS WITH FIBROMYALGIA

      Journal of clinical rheumatology
    15. BUKOWSKI RM; OLENCKI T; BOCOCK K; BUDD GT; PEEREBOOM D; MCLAIN D; GRIFFIN T
      PHASE-I TRIAL OF CAPECITABINE AND SUBCUTANEOUS INTERFERON-ALPHA IN RENAL-CELL CARCINOMA (RCC)

      Annals of oncology
    16. Rajagopalan, K; Peereboom, D; Budd, GT; Olencki, T; Murthy, S; Elson, P; McLain, D; Bukowski, R
      Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer

      INVESTIGATIONAL NEW DRUGS
    17. BUKOWSKI RM; OLENCKI T; WANG Q; PEEREBOOM D; BUDD GT; ELSON P; SANDSTROM K; TUASON L; RAYMAN P; TUBBS R; MCLAIN D; KLEIN E; NOVICK A; FINKE J
      PHASE-II TRIAL OF INTERLEUKIN-2 AND INTERFERON-ALPHA IN PATIENTS WITHRENAL-CELL CARCINOMA - CLINICAL-RESULTS AND IMMUNOLOGICAL CORRELATES OF RESPONSE

      Journal of immunotherapy with emphasis on tumor immunology
    18. BUDD GT; GANAPATHI R; ADELSTEIN DJ; PELLEY R; OLENCKI T; PETRUS J; MCLAIN D; ZHANG JL; CAPIZZI R; BUKOWSKI RM
      RANDOMIZED TRIAL OF CARBOPLATIN PLUS AMIFOSTINE VERSUS CARBOPLATIN ALONE IN PATIENTS WITH ADVANCED SOLID TUMORS

      Cancer
    19. HUSSEIN MA; WOOD L; MCLAIN D; BUKOWSKI RM
      DOXIL(R), VINCRISTINE AND DECADRON (DVD) IN THE MANAGEMENT OF MULTIPLE-MYELOMA (MM) PATIENTS (PTS) - A PRELIMINARY-REPORT

      Blood
    20. HUSSEIN MA; SNYDER J; FINKE J; RAYMAN P; MCLAIN D; ELSON P; BUKOWSKI RM
      THE EFFECT OF IL-2 MAINTENANCE (MN) THERAPY (TX) ON THE DURATION OF THE PLATEAU-PHASE IN RESPONDING MULTIPLE-MYELOMA (MM) PATIENTS (PTS)

      Blood
    21. FINKE J; MOLTO L; BLOOM T; KOLENKO V; POHLMAN B; LICHTIN A; MCLAIN D; TUBBS R; BUKOWSKI RM
      CD40L IS NOT EXPRESSED ON T-CELLS INFILTRATING NON-HODGKINS-LYMPHOMA B-CELLS AND IS POORLY INDUCED AFTER STIMULATION

      Blood
    22. FINKE J; BLOOM T; RAYMAN P; SNYDER J; MCLAIN D; BUKOWSKI RM; HUSSEIN MA
      ACTIVATION OF THE TRANSCRIPTION FACTOR NF-KAPPA-B IN PERIPHERAL-BLOODT-CELLS FROM MULTIPLE-MYELOMA PATIENTS IS IMPAIRED AND MAY CONTRIBUTETO THEIR INCREASED SUSCEPTIBILITY TO ACTIVATION-INDUCED APOPTOSIS

      Blood
    23. BUKOWSKI RM; OLENCKI T; GUNN H; MCLAIN D; BUDD GT; SANDSTROM K; TUASON L; REDOVAN C; RAYMAN P; TUBBS R; RESTA D; ELSON P; FINKE J
      PHASE-I TRIAL OF SUBCUTANEOUS INTERLEUKIN-3 IN PATIENTS WITH REFRACTORY MALIGNANCY - HEMATOLOGICAL, IMMUNOLOGICAL, AND PHARMACODYNAMIC FINDINGS

      Clinical cancer research
    24. OLENCKI T; FINKE J; TUBBS R; TUASON L; GREENE T; MCLAIN D; SWANSON SJ; HERZOG P; STANLEY T; EDINGER M; BUDD GT; BUKOWSKI RM
      IMMUNOMODULATORY EFFECTS OF INTERLEUKIN-2 AND INTERLEUKIN-4 IN PATIENTS WITH MALIGNANCY

      Journal of immunotherapy with emphasis on tumor immunology
    25. WOS E; OLENCKI T; TUASON L; BUDD GT; PEEREBOOM D; SANDSTROM K; MCLAIN D; FINKE J; BUKOWSKI RM
      PHASE-II TRIAL OF SUBCUTANEOUSLY ADMINISTERED GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA

      Cancer
    26. BUKOWSKI RM; DON W; REDOVAN C; MCLAIN D; SANDSTROM K; OLENCKI T; BUDD GT; PEEREBOOM D; GRIFFIN T; TANNENBAUM C; FINKE JK
      INDUCTION OF THE CXC CHEMOKINES IP-10 AND MIG IN PATIENTS (PTS) RECEIVING RHUIL-12 OR RIL-2

      Blood
    27. WILLIAMS CJ; ROCK M; CONSIDINE E; MCCARRON S; GOW P; LADDA R; MCLAIN D; MICHELS VM; MURPHY W; PROCKOP DJ; GANGULY A
      3 NEW POINT MUTATIONS IN TYPE-II PROCOLLAGEN (COL2A1) AND IDENTIFICATION OF A 4TH FAMILY WITH THE COL2A1 ARG519-]CYS BASE SUBSTITUTION USING CONFORMATION SENSITIVE GEL-ELECTROPHORESIS

      Human molecular genetics
    28. BUKOWSKI RM; MURTHY SA; FINKE J; CAULFIELD MJ; TUBBS R; HERZOG P; STANLEY J; EDINGER M; TUASON L; MCLAIN D; BUDD GT; OLENCKI T; GANAPATHI R
      PHASE-I TRIAL OF CISPLATIN, WR-2721, AND THE MURINE MONOCLONAL-ANTIBODY R24 IN PATIENTS WITH METASTATIC MELANOMA - CLINICAL AND BIOLOGIC EFFECTS

      Journal of immunotherapy with emphasis on tumor immunology
    29. BUKOWSKI RM; OLENCKI T; MCLAIN D; FINKE JH
      PLEIOTROPIC EFFECTS OF CYTOKINES - CLINICAL AND PRECLINICAL STUDIES

      Stem cells
    30. BUDD GT; LORENZI V; GANAPATHI R; ADELSTEIN D; PELLEY R; OLENCKI T; MCLAIN D; BUKOWSKI RM
      AMIFOSTINE - POTENTIAL FOR CLINICALLY USEFUL CYTOPROTECTION

      Supportive care in cancer
    31. BUKOWSKI RM; BUDD GT; GIBBONS JA; BAUER RJ; CHILDS A; ANTAL J; FINKE J; TUASON L; LORENZI V; MCLAIN D; TUBBS R; EDINGER M; THOMASSEN MJ
      PHASE-I TRIAL OF SUBCUTANEOUS RECOMBINANT MACROPHAGE-COLONY-STIMULATING FACTOR - CLINICAL AND IMMUNOMODULATORY EFFECTS

      Journal of clinical oncology
    32. BHATIA A; RICE TW; MCLAIN D; HERZOG P; BUDD GT; MURTHY S; KIRBY TJ; BUKOWSKI RM
      A PHASE-I TRIAL OF INTRAPLEURAL RECOMBINANT HUMAN INTERFERON-ALPHA (RHUIFN-ALPHA-2B) IN PATIENTS WITH MALIGNANT PLEURAL EFFUSIONS

      Journal of cancer research and clinical oncology
    33. RACKLEY R; NOVICK A; KLEIN E; BUKOWSKI R; MCLAIN D; GOLDFARB D
      THE IMPACT OF ADJUVANT NEPHRECTOMY ON MULTIMODALITY TREATMENT OF METASTATIC RENAL-CELL CARCINOMA

      The Journal of urology
    34. SAMPAIO CA; MCLAIN D; KLEIN E; BUKOWSKI RM
      RENAL MASSES SIMULATING PRIMARY RENAL-CELL CARCINOMA IN PATIENTS WITHADVANCED MALIGNANCIES

      The Journal of urology
    35. BUKOWSKI RM; OLENCKI T; MCLAIN D; TUASON L; BUDD GT; SANDSTROM K; RAYMAN P; GUNN H; LEVITT D; FINKE J
      PHARMACOKINETICS AND PHARMACODYNAMICS OF RECOMBINANT INTERLEUKIN-3 (RHIL-3) FOLLOWING SUBCUTANEOUS (SQ) ADMINISTRATION TO PATIENTS WITH REFRACTORY MALIGNANCIES

      Blood
    36. WOS E; OLENCKI T; BUDD GT; PEEREBOOM D; FINKE J; WOOD L; MCLAIN D; TUBBS R; REDOVAN C; EDINGER M; LEVITT D; BUKOWSKI RM
      HEMATOLOGIC EFFECTS OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (RHUGM-CSF) AND INTERLEUKIN-6 (RHIL-6) ADMINISTERED TO PATIENTS WITH MALIGNANCY

      Blood
    37. THOMASSEN MJ; ANTAL JM; CONNORS MJ; MCLAIN D; SANDSTROM K; MEEKER DP; BUDD GT; LEVITT D; BUKOWSKI RM
      IMMUNOMODULATORY EFFECTS OF RECOMBINANT INTERLEUKIN-3 TREATMENT ON HUMAN ALVEOLAR MACROPHAGES AND MONOCYTES

      Journal of immunotherapy with emphasis on tumor immunology
    38. BUKOWSKI RM; MURTHY S; MCLAIN D; FINKE J; ANDRESEN S; TUBBS R; BAUER L; GIBSON V; BUDD GT; THOMASSEN MJ
      PHASE-I TRIAL OF RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN PATIENTS WITH LUNG-CANCER - CLINICAL AND IMMUNOLOGICAL EFFECTS

      Journal of immunotherapy with emphasis on tumor immunology
    39. BUDD GT; GANAPATHI R; BAUER L; MURTHY S; ADELSTEIN D; WEICK J; GIBSON V; MCLAIN D; SERGI J; BUKOWSKI RM
      PHASE-I STUDY OF WR-2721 AND CARBOPLATIN

      European journal of cancer
    40. BUKOWSKI RM; YOUNG J; GOODMAN G; MEYERS F; ISSELL BF; SERGI JS; MCLAIN D; FYFE G; FINKE J
      POLYETHYLENE-GLYCOL CONJUGATED INTERLEUKIN-2 - CLINICAL AND IMMUNOLOGICAL EFFECTS IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA

      Investigational new drugs
    41. OLENCKI T; BUDD GT; MURTHY S; FINKE J; HERZOG P; MCLAIN D; TUBBS R; TUASON L; EDINGER M; LEVITT D; BUKOWSKI RM
      CYTOKINE GENE-EXPRESSION AND SECRETION - EFFECTS OF RHIL-6 IN CANCER-PATIENTS

      Blood
    42. WILLIAMS CJ; MCCARRON S; CONSIDINE E; MCLAIN D; MURPHY W; GANGULY A; ROCK M; PROCKOP DJ
      A POINT MUTATION IN ONE ALLELE OF THE TYPE-II PROCOLLAGEN GENE PRODUCES A GLY(976) -] SER SUBSTITUTION OF THE GENE IN A FAMILY WITH SEVERE DEGENERATIVE ARTHROPATHY OF THE HIPS ASSOCIATED WITH PROBABLE EPIPHYSEAL DYSPLASIA

      American journal of human genetics


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/10/20 alle ore 02:09:46